Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Datroway Grabs Positive CHMP Opinion in 1st-Line TNBC
Daiichi Sankyo said on June 26 that a key European regulatory panel has given the blessing for a label expansion of its TROP2-directed antibody drug conjugate Datroway (datopotamab deruxtecan) for the treatment of triple-negative breast cancer (TNBC). The European Medicines…
To read the full story
Related Article
- Datroway Lands EU Approval in 1st-Line TNBC
August 3, 2026
- Datroway Snares US Approval in 1st-Line TNBC: Daiichi Sankyo
May 25, 2026
- Datroway Filed for 1st-Line TNBC in Japan: Daiichi Sankyo
February 13, 2026
- Datroway Accepted for US Review for 1st-Line TNBC: Daiichi Sankyo
February 4, 2026
- Datroway Accepted for European Review for 1st Line TNBC
December 19, 2025
- Datroway Hits Key Goals in Global PIII Trial for TNBC: Daiichi Sankyo
October 7, 2025
- Daiichi Sankyo’s Datroway Approved in Europe for Breast Cancer
April 9, 2025
BUSINESS
- Lilly Confirms Orforglipron Diabetes Filings in US, Japan
August 7, 2026
- Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
- Inrebic Expands First-Line Treatment Options for Myelofibrosis: Expert
August 7, 2026
- Meiji Pharma Drops Hiyasta Development in B-Cell NHL
August 7, 2026
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…